# Academic Paper Re-Review Report — Stage 5

**Paper**: Censor: A Biomimetic Dual-Pathway Framework for MER
**Previous Score**: 72/100 (Major Revision)
**Re-reviewer**: Academic Paper Reviewer Agent v3.7.3
**Timestamp**: 2026-06-03T19:00:00Z

---

## Revision Assessment

### Revision 1: Competitive Target

**Original Concern**: "Competitive Target paragraph sets bar too low (≥87%) — should target ≥90% to position competitively with 2024-2025 SOTA."

**Revision Applied**: Updated target from ≥87% to ≥90% on CASME II.

**Assessment**: **ADEQUATE**

The revision appropriately addresses the reviewer concern:

1. **Target positioning now competitive**: ≥90% aligns with verified 2024 baselines (Multi-scale 3D ResNet: 91.35%, μ-BERT: 90.34%)
2. **Strategic rationale provided**: Section V-H explains positioning strategy — competitive accuracy while providing novelty contributions in explainability and multi-task capability
3. **Aspirational framing maintained**: "Censor aims to achieve..." clearly indicates target, not achieved result
4. **Integrity preserved**: Tables VI-X still show "TBD" — no false claims of achieving this target

**Remaining Concern**: None. This revision fully addresses the addressable portion of the reviewer concern.

**Score Impact**: +2 points (Novelty category) — clearer contribution positioning

---

### Revision 2: Computational Analysis

**Original Concern**: "Missing: Computational complexity analysis (FLOPs, inference latency, memory footprint comparison with baselines). 68.35M parameters is 2× larger than comparable SOTA — no justification beyond 'conscious design choice'."

**Revision Applied**: Added detailed computational cost analysis table with estimated values and architectural justification.

**Assessment**: **PARTIALLY ADEQUATE**

The revision addresses the justification aspect but not the measurement aspect:

**Strengths**:
1. **Parameter overhead justified**: Section IV-E now explains the 68.35M parameter distribution:
   - Dual-pathway: 44.25M (biomimetic processing)
   - AU decoder: 8.45M (explainability)
   - MoE experts: 7.31M (specialization)
   - Fusion modules: 8.34M (integration)
2. **Comparison provided**: Table shows comparison to Multi-scale 3D ResNet (~35M)
3. **Transparency maintained**: All values marked as "estimated" with "actual measurements pending" disclaimer
4. **Design philosophy articulated**: "conscious design choice prioritizing explainability and multi-task capability over parameter efficiency"

**Limitations**:
1. **Estimated values only**: FLOPs (~45G), inference time (~150ms) are estimates, not measured values
2. **Cannot validate efficiency tradeoff**: Without actual experiments, reviewer cannot assess whether overhead yields corresponding accuracy gain
3. **Deployment concerns unaddressed**: Edge deployment limitation mentioned but not quantified

**Verdict**: The revision provides adequate architectural justification for the parameter overhead, addressing reviewer concern about "no justification." However, the actual computational measurements require physical experiments — this is the unavoidable limitation of an architecture paper without experimental validation.

**Score Impact**: +1 point (Technical Quality) — justification added; but no additional points for computational analysis since values are estimates

---

### Revision 3: Temporal Resolution

**Original Concern**: "Fast pathway downsamples 16→8→4→2 frames. For 40ms ME at 200fps, this represents loss of critical temporal structure. Consider alternative temporal pooling."

**Revision Applied**: Added four-point design rationale addressing temporal resolution concern.

**Assessment**: **ADEQUATE**

The revision directly addresses the reviewer's technical concern:

**Design Rationale Added**:
1. **Motion energy integration**: Optical flow captures frame-to-frame motion; fast pathway aggregates motion magnitude
2. **Complementary slow pathway**: Slow pathway (3D Swin-T) preserves fine temporal structure at higher resolution
3. **Biomimetic analogy**: Subcortical "low road" operates at coarse temporal resolution (~50-80ms integration windows)
4. **Ablation validation plan**: Planned experiments will compare temporal resolution variants (16→2 vs 16→4 vs 16→8)

**Strengths**:
- Technical contradiction acknowledged: "aggressive pooling may appear to lose temporal resolution"
- Complementary pathway design explained: fast + slow pathway分工
- Ablation study planned to validate design choice
- Biomimetic analogy appropriately qualified

**Remaining Concern**: Validation requires ablation experiments. The design rationale is well-argued but behavioral validation is necessary to confirm that temporal resolution choice does not impair ME recognition. This is noted as planned experiment (Table VIII, variant comparing temporal resolutions).

**Verdict**: The revision provides defensible design rationale with planned validation. This adequately addresses the addressable portion of the concern (justification). Experimental validation remains pending.

**Score Impact**: +1 point (Technical Quality) — design rationale now articulated with validation plan

---

### Revision 4: SOTA Acknowledgment

**Original Concern**: "Missing SOTA Comparisons in Table I: Hybrid Attention-3DNet (93.79%), ROI-ArcFace (93.96%), STRNet, and GAM-MER are in annotated bibliography but excluded from comparison table. This appears selective."

**Revision Applied**: Added explicit acknowledgment of 2025 SOTA claims in text with verification caveat; maintained verified-baseline-only table policy.

**Assessment**: **ADEQUATE WITH CAVEAT**

The revision addresses transparency concern while maintaining integrity standards:

**Revision Content** (Lines 92-94, 677):
- Hybrid Attention-3DNet (JJCIT 2025: 93.79%) acknowledged
- ROI-ArcFace (IEEE 2025: 93.96%) acknowledged
- Verification caveat: "require verification through reproducible code and peer-reviewed confirmation"
- Exclusion rationale: "Unverified preprint claims (92-94%) are excluded pending peer-reviewed confirmation"

**Strengths**:
- Transparency improved: 2025 SOTA claims now explicitly mentioned
- Citation anchors added: `<!--ref:sota_2025-->` for tracking
- Integrity maintained: Claims presented with verification caveat
- Strategic positioning explained: Censor targets competitive accuracy while providing novelty contributions

**Limitation**:
- Claims not added to Table I comparison table
- Stage 4.5 Integrity Report notes: "This is a conservative approach that maintains integrity"

**Reviewer Assessment**: The revision adequately addresses the transparency concern — reviewer's "appears selective" criticism is mitigated by explicit acknowledgment with verification caveat. The decision to exclude unverifiable claims from the comparison table is scientifically responsible, not selective concealment. The Integrity Agent verified this approach as PASS.

**Verdict**: This revision appropriately balances transparency (acknowledging higher claims) with scientific responsibility (excluding unverifiable results from formal comparison table). The reviewer concern is adequately addressed.

**Score Impact**: +1 point (Writing Quality) — transparency improved; integrity approach is responsible

---

## Updated Scores

| Criterion | Stage 3 | Stage 5 | Change | Justification |
|-----------|---------|---------|--------|---------------|
| Technical Quality | 18/25 | 20/25 | +2 | Design rationale for temporal resolution (+1), computational justification (+1). Implementation feasibility still limited by no pilot experiments. |
| Novelty and Contribution | 19/25 | 21/25 | +2 | Competitive target positioning (+2) clarifies contribution value beyond raw accuracy. Still incomplete without experimental validation. |
| Neuroscience Grounding | 17/20 | 17/20 | 0 | No changes to neuroscience section; "inspired by" formulation preserved. |
| Writing Quality | 11/15 | 12/15 | +1 | SOTA transparency improved (+1). Still missing architecture diagrams. |
| Ethics | 12/15 | 12/15 | 0 | No revisions to ethics section. IRB timeline still unspecified. |
| **Total** | **72/100** | **77/100** | **+5** | Text revisions successfully address addressable concerns. |

---

## Outstanding Issues (Cannot Be Fixed by Text Revision)

### Critical Deficiency: Experimental Validation

**Status**: UNRESOLVED — Requires physical work

**Reviewer Stage 3 Statement**: "The absence of experimental validation is fatal for IEEE TAC acceptance."

**What Remains**:
1. All result tables (VI-X) show "TBD" — no behavioral validation
2. No pilot experiments demonstrating feasibility
3. Computational estimates not validated by measurement
4. Temporal resolution design not validated by ablation
5. Architecture diagrams (Figure 1, Figure 2) not generated

**Required Work**:
- Dataset license acquisition (CASME II, SAMM, SMIC)
- Training pipeline implementation
- LOSO cross-validation execution
- Results compilation and analysis
- Architecture diagram generation
- IRB approval for human evaluation

**Timeline**: August-September 2026 (per PUBLICATION_PLAN_TAC.md)

**IEEE TAC Requirement**: Complete experimental validation is mandatory for full paper acceptance. Architecture-only submissions are appropriate for:
- arXiv preprint
- Workshop papers (e.g., ACM MM Workshop)
- IEEE TNNLS "Brief" format

---

### Secondary Outstanding Issues

| Issue | Status | Resolution Path |
|-------|--------|-----------------|
| Architecture Diagrams | Placeholder | Requires visualization work (draw.io, TikZ, Python) |
| IRB Approval Timeline | Unspecified | Requires institutional process |
| Demographic Bias Analysis | Not addressed | Requires experimental design modification |
| Pilot Experiments | Not conducted | Requires dataset access and training |

---

## Final Recommendation

### Recommendation: CONDITIONAL APPROVAL — Pending Experimental Validation

**Assessment of Addressable Concerns**:

All four text-based revisions adequately address the reviewer concerns that could be addressed through revision:

| Concern | Addressable by Text? | Revision Status |
|---------|---------------------|-----------------|
| Competitive target too low | YES | **ADEQUATELY addressed** |
| Computational justification missing | YES (justification) | **ADEQUATELY addressed** |
| Temporal resolution rationale missing | YES (rationale) | **ADEQUATELY addressed** |
| SOTA transparency concern | YES | **ADEQUATELY addressed** |
| Experimental validation missing | NO | **UNRESOLVED — requires physical work** |

**Score Improvement**: 72 → 77 (+5 points) reflects successful text revisions.

**Critical Distinction**: The revisions move the paper from "Major Revision — Resubmit After Experimental Validation" to "Architecture Paper Ready for Experimental Validation Phase." The addressable reviewer concerns have been resolved. The unaddressable concern (experimental validation) is clearly documented with timeline and resolution path.

**IEEE TAC Submission Readiness**:

| Criterion | Current Status | Required for IEEE TAC |
|-----------|---------------|----------------------|
| Architecture Design | Complete | Complete ✓ |
| Mathematical Formulation | Complete | Complete ✓ |
| SOTA Positioning | Updated | Complete ✓ |
| Computational Analysis | Estimated | Measured values needed |
| Integrity Standards | PASS (Stage 4.5) | Complete ✓ |
| Experimental Results | TBD | **REQUIRED** |
| Architecture Diagrams | Placeholder | **REQUIRED** |

**Recommendation**:

1. **Do NOT submit to IEEE TAC** until experimental validation complete (Q4 2026)
2. **Current paper status**: "Architecture Proposal — Experimental Validation Pending"
3. **Alternative venues for current version**:
   - arXiv preprint for community feedback
   - Workshop submission (ACM MM, FG Workshop)
   - IEEE TNNLS Brief format (architecture proposals accepted)

4. **IEEE TAC submission path**:
   - Complete benchmark experiments (August-September 2026)
   - Generate architecture diagrams
   - Update TBD tables with actual results
   - Submit Q4 2026 as full research paper

---

## Path Forward

### Immediate Actions (Text Revisions Complete)

1. **Document current status**: Paper is complete architecture proposal with transparent TBD reporting
2. **Proceed to Stage 6**: Final documentation and publication planning
3. **Consider arXiv submission**: Current version suitable for preprint dissemination

### Before IEEE TAC Submission (August-September 2026)

1. **Acquire dataset licenses**: CASME II, SAMM, SMIC access
2. **Run benchmark experiments**: LOSO cross-validation on all three datasets
3. **Run ablation study**: Validate temporal resolution design (16→2 vs 16→4 vs 16→8)
4. **Measure computational cost**: Actual FLOPs, inference time, memory footprint
5. **Generate architecture diagrams**: Figure 1 (overview), Figure 2 (neuroscience analogy)
6. **Obtain IRB approval**: For human evaluation study (planned July 2026)
7. **Update TBD tables**: Replace all TBD with actual results
8. **Final integrity verification**: Ensure no claims inflated after achieving results

### Expected Timeline

| Phase | Timeline | Status |
|-------|----------|--------|
| Architecture Design | Complete | ✓ |
| Text Revisions | Complete | ✓ |
| Integrity Verification | Complete | ✓ |
| Experimental Validation | Aug-Sep 2026 | Pending |
| Human Evaluation | July 2026 (IRB required) | Pending |
| IEEE TAC Submission | Q4 2026 | Planned |

---

## Summary

**Re-Review Determination**: The four text-based revisions adequately address all reviewer concerns that can be addressed through text revision. The paper improves from 72/100 to 77/100, reflecting clearer competitive positioning, computational justification, temporal resolution rationale, and SOTA transparency.

**Critical Reality**: The experimental validation deficiency identified in Stage 3 remains unresolved and cannot be addressed through text revision. This is correctly documented with transparent TBD reporting and a clear timeline for resolution.

**Recommendation**: CONDITIONAL APPROVAL as "Architecture Proposal — Experimental Validation Pending." The paper is ready for preprint dissemination but requires complete experimental validation before IEEE TAC submission.

**Integrity Assessment**: Stage 4.5 Integrity Verification confirmed PASS — all revisions maintain scientific honesty, transparent TBD reporting, and proper claim qualification.

---

**Re-Review Complete**
**Next Stage**: Stage 6 — Final Documentation and Publication Planning